Telapristone

Drug Profile

Telapristone

Alternative Names: CBD4124; CDB-4124; Proellex; Proellex®-V; Progenta; Telapristone acetate

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator National Institute of Child Health and Human Development
  • Developer Northwestern University Feinberg School of Medicine; Repros Therapeutics
  • Class Antiprogestogens; Norpregnadienes; Small molecules
  • Mechanism of Action Selective progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Endometriosis; Uterine leiomyoma
  • Suspended Anaemia

Most Recent Events

  • 17 Apr 2017 Repros Therapeutics has patent protection for telapristone acetate in USA
  • 10 Apr 2017 Repros Therapeutic meets the US FDA in a Type C/ Guidance meeting for the development of oral telapristone for the treatment of Uterine fibroids
  • 19 Dec 2016 Updated efficacy data from the phase II ZPE-201 trial in Endometriosis released by Repros Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top